Market Place
Sourcing Support
All News #Library
Others
Actinogen Gets DMC Nod for XanaMIA Alzheimer`s Trial
02 Feb 2026 //
GLOBENEWSWIRE
Actinogen Confirms Xanamem Tablet Exposures in Trial Settings
27 Aug 2025 //
PR NEWSWIRE
Actinogen updates Alzheimer`s trial enrollment and business news
30 Apr 2025 //
GLOBENEWSWIRE
Actinogen`s Xanamem Study Published In Pharmacology Journal
12 Feb 2025 //
PR NEWSWIRE
Actinogen Announces Emestedastat as Nonproprietary Name for Xanamem
05 Feb 2025 //
PR NEWSWIRE
Actinogen Randomize 1st US Participant in XanaMIA Alzheimer`s Trial
09 Dec 2024 //
PR NEWSWIRE
Actinogen Reports Positive Depression Results In XanCIDD Phase 2a Trial
27 Aug 2024 //
PR NEWSWIRE
Actinogen`s Xanamem Shows Significant Results In Depression Trial
12 Aug 2024 //
PR NEWSWIRE
Actinogen XanaCIDD Phase 2a Cognition, Depression Trial Completes Enrollment
22 Apr 2024 //
PR NEWSWIRE
First Patient Dosed In Actinogen`s XanaMIA Alzheimer`s Phase 2b
15 Apr 2024 //
PR NEWSWIRE
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum
13 Oct 2023 //
PR NEWSWIRE
Actinogen optimizes XanaMIA Phase 2b Alzheimer`s disease trial design
26 Sep 2023 //
PR NEWSWIRE
Actinogen to present progress on Cognitive Impairment Phase 2 trials
31 May 2023 //
PR NEWSWIRE
Actinogen presents positive Phase 2a Xanamem data in at ADPD
30 Mar 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.